The management of prostate cancer continues to move toward increasingly individualized care, with advances in imaging, biopsy techniques, molecular imaging and minimally invasive treatment helping physicians more precisely identify clinically significant disease and tailor therapy to the individual patient.

For Manuel Ozambela Jr., M.D., urologic surgical oncologist at Baptist Health Herbert Wertheim Cancer Institute, the central challenge is balancing oncologic control with preservation of urinary and sexual function.

“I want to cure the patient’s cancer, but I also want to preserve their quality of life,” Dr. Ozambela says.

PSA as the Starting Point for Risk Assessment

Because most prostate cancers are diagnosed before symptoms develop, prostate-specific antigen testing remains an important entry point into the diagnostic pathway.

“Most men will be completely asymptomatic,” Dr. Ozambela said. “They’re often diagnosed far before they have symptoms.”

PSA, however, should not be interpreted as a binary marker of malignancy. Dr. Ozambela emphasizes that values must be considered in the context of age, prostate size, clinical history and PSA trends. Benign prostatic hyperplasia and urinary tract infection can also elevate PSA.

For younger men, he notes that a PSA above approximately 3 ng/mL may warrant repeat testing and further evaluation, depending on the clinical context.

Family history also informs risk assessment. A first-degree relative with prostate cancer may increase risk, while patterns of breast, pancreatic or uterine cancer within a family can suggest an inherited cancer predisposition.

Dr. Ozambela also notes that Black men have been observed to develop prostate cancer at younger ages and, in some cases, present with more aggressive disease.

MRI and Targeted Biopsy Refine Diagnosis

When PSA or other clinical factors raise concern, multiparametric prostate MRI can provide additional information about gland size, anatomy and suspicious lesions.

MRI findings can subsequently guide targeted biopsy. MRI-ultrasound fusion techniques allow clinicians to direct tissue sampling toward areas considered at greatest risk while obtaining the histopathologic information required for diagnosis.

“Our imaging technology is much better,” Dr. Ozambela says. “We’re better able to identify patients who have prostate cancer, and also the type of prostate cancer that needs treatment.”

Once malignancy is confirmed, the emphasis shifts from simply establishing the diagnosis to defining its clinical significance.

“The next step should be understanding what the true risk of that particular cancer is for that patient,” he said.

Age, overall health, PSA, prostate size, symptoms, tumor characteristics and the patient’s goals all contribute to treatment planning. Lower-grade, indolent disease may be appropriate for observation or surveillance, while patients with more clinically significant disease may require definitive treatment.

Expanding Options for Localized Disease

Management may include prostatectomy, radiation therapy or, in appropriately selected patients, focal therapy.

Robotic surgery has continued to evolve from conventional multiport approaches to single-port systems that allow some procedures to be performed through a single small incision.

At the same time, improvements in imaging have opened the door to greater treatment selectivity. Rather than treating the entire gland in every case, focal therapy seeks to ablate the cancerous portion of the prostate while preserving uninvolved tissue.

Dr. Ozambela describes modalities including high-intensity focused ultrasound, which uses thermal energy, and irreversible electroporation, in which electrical energy is delivered through needles positioned within the prostate.

Patient selection remains essential, however.

“As urologic oncologic surgeons, we have a lot of tools now,” he notes. “It’s important that you use the right tool for the right patient, not try to have the patient fit your tool.”

That individualized approach is particularly relevant when counseling patients about treatment-related urinary incontinence and erectile dysfunction. Advances in operative technique and more targeted treatment strategies are intended not only to achieve cancer control but also to support faster functional recovery.

PSMA Imaging Changes Staging and Recurrence Evaluation

Prostate-specific membrane antigen (PSMA) imaging has also substantially expanded physicians’ ability to localize disease.

This molecular imaging approach can identify sites of prostate cancer throughout the body. For patients with higher-risk disease, it can help clarify whether malignancy remains confined to the prostate or extends beyond the gland.

Following definitive therapy, PSMA imaging may also help localize recurrent disease and inform subsequent management.

“It tells and informs a physician where the cancer is,” Dr. Ozambela says, calling the technology “a game changer.”

AI May Further Integrate Risk Information

Artificial intelligence represents another emerging component of prostate cancer evaluation. Dr. Ozambela says. AI-based tools are already being used to assist in MRI interpretation and potentially identify suspicious areas that warrant closer evaluation.

The broader opportunity, he believes, may be in integrating imaging, pathology and clinical characteristics to improve risk stratification and treatment selection.

For clinicians, these technologies increasingly support a central principle of contemporary prostate cancer care: treatment intensity should reflect both the biology of the disease and the priorities of the individual patient.

“Cancer control” remains the first objective, Dr. Ozambela says, but modern prostate cancer management must also consider functional outcomes, recovery and quality of life.